Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

Inclusion Criteria: * Adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative Exclusion Criteria: * \* Any optic neuropathy for which the diagnosis of LHON is not formally confirmed or genetically proven; * LHON that started for more than 5 years; * LHON associated with another primary mutation than 3460 or 11778 * Children or adult patients under guardianship or deprived of liberty by administrative or judicial decision; * Women of childbearing age ; pregnant or lactating women; * Patients who do not have affiliation to a social protection scheme (national or private insurance / beneficiary or assignee); * Patient who did not give its written, informed and signed consent; * Allergy to fibrate, bezafibrate and / or BEFIZAL® 200mg (Arrow Generiques) or one of these constituents; * Photosensitivity reactions related to fibrates; * Patient already receiving treatment with fibrates or HMG Co-A reductase inhibitors or anticoagulants; * Hepatic insuffisiency or dysfunction with increased of transaminases (AST and ALT) over 3 times of the normal; * Renal insufficiency with serum creatinine\> 15 mg / L (\> 135 mg / dL) Biliary pathology